{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:01:38Z","timestamp":1782889298432,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021QH008"],"award-info":[{"award-number":["ZR2021QH008"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024YQ073"],"award-info":[{"award-number":["ZR2024YQ073"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010031","name":"Postdoctoral Research Foundation of China","doi-asserted-by":"publisher","award":["2023M731484"],"award-info":[{"award-number":["2023M731484"]}],"id":[{"id":"10.13039\/501100010031","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203218"],"award-info":[{"award-number":["82203218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00259-025-07201-6","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T01:19:05Z","timestamp":1742606345000},"page":"3211-3222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Relationship between PD-L1 expression and [18F]FAPI versus [18F]FDG uptake on PET\/CT in lung cancer"],"prefix":"10.1007","volume":"52","author":[{"given":"Jingjie","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouhui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7198-9915","authenticated-orcid":false,"given":"Yuchun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"issue":"3","key":"7201_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"Cancer J Clin"},{"issue":"328","key":"7201_CR2","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway Blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv4. https:\/\/doi.org\/10.1126\/scitranslmed.aad7118.","journal-title":"Sci Transl Med"},{"issue":"19","key":"7201_CR3","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 Blockade. Proc Natl Acad Sci USA. 2002;99(19):12293\u20137. https:\/\/doi.org\/10.1073\/pnas.192461099.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7201_CR4","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3389\/fimmu.2016.00550","volume":"7","author":"K Bardhan","year":"2016","unstructured":"Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1\/2 pathway from discovery to clinical implementation. Front Immunol. 2016;7:550. https:\/\/doi.org\/10.3389\/fimmu.2016.00550.","journal-title":"Front Immunol"},{"issue":"6","key":"7201_CR5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD. First-Line immunotherapy for Non-Small-Cell lung cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2022;40(6):586\u201397. https:\/\/doi.org\/10.1200\/JCO.21.01497.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"9","key":"7201_CR6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S1470-2045(23)00329-7)","volume":"24","author":"M \u00d6zg\u00fcro\u011flu","year":"2023","unstructured":"\u00d6zg\u00fcro\u011flu M, Kilickap S, Sezer A, G\u00fcm\u00fc\u015f M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Ho GF, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, He X, Kaul M, Okoye E, Li Y, Li S, Pouliot JF, Rietschel P. First-line Cemiplimab monotherapy and continued Cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(9):989\u20131001. https:\/\/doi.org\/10.1016\/S1470-2045(23)00329-7).","journal-title":"Lancet Oncol"},{"issue":"3","key":"7201_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00259-023-06480-1","volume":"51","author":"S Zhu","year":"2024","unstructured":"Zhu S, Liang B, Zhou Y, Chen Y, Fu J, Qiu L, Lin J. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy. Eur J Nucl Med Mol Imaging. 2024;51(3):625\u201340. https:\/\/doi.org\/10.1007\/s00259-023-06480-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7201_CR8","doi-asserted-by":"publisher","first-page":"105294","DOI":"10.1016\/j.bioorg.2021.105294","volume":"115","author":"G Lv","year":"2021","unstructured":"Lv G, Miao Y, Chen Y, Lu C, Wang X, Xie M, Qiu L, Lin J. Promising potential of a 18F-labelled small-molecular Radiotracer to evaluate PD-L1 expression in tumors by PET imaging. Bioorg Chem. 2021;115:105294. https:\/\/doi.org\/10.1016\/j.bioorg.2021.105294.","journal-title":"Bioorg Chem"},{"issue":"9","key":"7201_CR9","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1101\/gad.279737.116","volume":"30","author":"P Gascard","year":"2016","unstructured":"Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev. 2016;30(9):1002\u201319. https:\/\/doi.org\/10.1101\/gad.279737.116.","journal-title":"Genes Dev"},{"issue":"1","key":"7201_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.acra.2013.09.015)","volume":"21","author":"G Treglia","year":"2014","unstructured":"Treglia G, Sadeghi R, Annunziata S, Lococo F, Cafarotti S, Bertagna F, Prior JO, Ceriani L, Giovanella L. Diagnostic accuracy of 18F-FDG-PET and PET\/CT in the differential diagnosis between malignant and benign pleural lesions: a systematic review and meta-analysis. Acad Radiol. 2014;21(1):11\u201320. https:\/\/doi.org\/10.1016\/j.acra.2013.09.015).","journal-title":"Acad Radiol"},{"issue":"2","key":"7201_CR11","doi-asserted-by":"publisher","first-page":"e222785","DOI":"10.1148\/radiol.222785","volume":"308","author":"Y Wei","year":"2023","unstructured":"Wei Y, Ma L, Li P, Lu J, Ren J, Yan S, Wu H, Yuan S, Fu Z, Yu J. FAPI compared with FDG PET\/CT for diagnosis of primary and metastatic lung cancer. Radiology. 2023;308(2):e222785. https:\/\/doi.org\/10.1148\/radiol.222785.","journal-title":"Radiology"},{"issue":"1","key":"7201_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1148\/radiol.211424","volume":"303","author":"L Wang","year":"2022","unstructured":"Wang L, Tang G, Hu K, Liu X, Zhou W, Li H, Huang S, Han Y, Chen L, Zhong J, Wu H. Comparison of 68Ga-FAPI and 18F-FDG PET\/CT in the evaluation of advanced lung cancer. Radiology. 2022;303(1):191\u20139. https:\/\/doi.org\/10.1148\/radiol.211424.","journal-title":"Radiology"},{"issue":"11","key":"7201_CR13","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.2967\/jnumed.124.268557","volume":"65","author":"Y Dong","year":"2024","unstructured":"Dong Y, Wang Z, Hu X, Sun Y, Qin J, Qin Q, Liu S, Yuan S, Yu J, Wei Y. [18F]AlF-NOTA-FAPI-04 PET\/CT for predicting pathologic response of resectable esophageal squamous cell carcinoma to neoadjuvant camrelizumab and chemotherapy: A phase II clinical trial. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2024;65(11):1702\u20139. https:\/\/doi.org\/10.2967\/jnumed.124.268557.","journal-title":"Soc Nuclear Med"},{"issue":"2","key":"7201_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The eighth edition AJCC cancer staging manual: continuing to build a Bridge from a population-based to a more personalized approach to cancer staging. Cancer J Clin. 2017;67(2):93\u20139. https:\/\/doi.org\/10.3322\/caac.21388.","journal-title":"Cancer J Clin"},{"issue":"5","key":"7201_CR15","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00259-021-05638-z","volume":"49","author":"Y Wei","year":"2022","unstructured":"Wei Y, Cheng K, Fu Z, Zheng J, Mu Z, Zhao C, Liu X, Wang S, Yu J, Yuan S. [18F]AlF-NOTA-FAPI-04 PET\/CT uptake in metastatic lesions on PET\/CT imaging might distinguish different pathological types of lung cancer. Eur J Nucl Med Mol Imaging. 2022;49(5):1671\u201381. https:\/\/doi.org\/10.1007\/s00259-021-05638-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"16","key":"7201_CR16","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-20-0798","volume":"26","author":"I Eguren-Santamaria","year":"2020","unstructured":"Eguren-Santamaria I, Sanmamed MF, Goldberg SB, Kluger HM, Idoate MA, Lu BY, Corral J, Schalper KA, Herbst RS, Gil-Bazo I. PD-1\/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice. Clin cancer Research: Official J Am Association Cancer Res. 2020;26(16):4186\u201397. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0798.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"7","key":"7201_CR17","doi-asserted-by":"publisher","first-page":"e196879","DOI":"10.1001\/jamanetworkopen.2019.6879","volume":"2","author":"Y Yu","year":"2019","unstructured":"Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y, Lin D, Gao Q, Zhou H, Liao W, Yao H. Association of survival and Immune-Related biomarkers with immunotherapy in patients with Non-Small cell lung cancer: A Meta-analysis and individual Patient-Level analysis. JAMA Netw Open. 2019;2(7):e196879. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.6879.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"7201_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.annonc.2020.01.065","volume":"31","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Rizvi H, Bandlamudi C, Sauter JL, Travis WD, Rekhtman N, Plodkowski AJ, Perez-Johnston R, Sawan P, Beras A, Egger JV, Ladanyi M, Arbour KC, Rudin CM, Riely GJ, Taylor BS, Donoghue MTA, Hellmann MD. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Annals Oncology: Official J Eur Soc Med Oncol. 2020;31(5):599\u2013608. https:\/\/doi.org\/10.1016\/j.annonc.2020.01.065.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"19","key":"7201_CR19","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin cancer Research: Official J Am Association Cancer Res. 2014;20(19):5064\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3271.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"3","key":"7201_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133\u201350. https:\/\/doi.org\/10.1038\/s41568-019-0116-x.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"7201_CR21","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1038\/s41467-018-07767-w","volume":"9","author":"Q Jia","year":"2018","unstructured":"Jia Q, Wu W, Wang Y, Alexander PB, Sun C, Gong Z, Cheng JN, Sun H, Guan Y, Xia X, Yang L, Yi X, Wan YY, Wang H, He J, Futreal PA, Li QJ, Zhu B. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun. 2018;9(1):5361. https:\/\/doi.org\/10.1038\/s41467-018-07767-w.","journal-title":"Nat Commun"},{"issue":"5","key":"7201_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ccr.2012.08.013","volume":"22","author":"A Calon","year":"2012","unstructured":"Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, C\u00e9spedes MV, Sevillano M, Nadal C, Jung P, Zhang XH, Byrom D, Riera A, Rossell D, Mangues R, Massagu\u00e9 J, Sancho E, Batlle E. Dependency of colorectal cancer on a TGF-\u03b2-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012;22(5):571\u201384. https:\/\/doi.org\/10.1016\/j.ccr.2012.08.013.","journal-title":"Cancer Cell"},{"issue":"9","key":"7201_CR23","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582\u201398. https:\/\/doi.org\/10.1038\/nrc.2016.73.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"7201_CR24","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/s41467-018-03347-0","volume":"9","author":"MA Lakins","year":"2018","unstructured":"Lakins MA, Ghorani E, Munir H, Martins CP, Shields JD. Cancer-associated fibroblasts induce antigen-specific deletion of CD8\u2009+\u2009T cells to protect tumour cells. Nat Commun. 2018;9(1):948. https:\/\/doi.org\/10.1038\/s41467-018-03347-0.","journal-title":"Nat Commun"},{"key":"7201_CR25","doi-asserted-by":"publisher","unstructured":"Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Volume 330. Science (New York; 2010. pp. 827\u201330. 6005https:\/\/doi.org\/10.1126\/science.1195300.","DOI":"10.1126\/science.1195300"},{"issue":"7","key":"7201_CR26","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2967\/jnumed.121.262426","volume":"63","author":"CE Mona","year":"2022","unstructured":"Mona CE, Benz MR, Hikmat F, Grogan TR, Lueckerath K, Razmaria A, Riahi R, Slavik R, Girgis MD, Carlucci G, Kelly KA, French SW, Czernin J, Dawson DW, Calais J. Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: interim analysis of a prospective translational exploratory study. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2022;63(7):1021\u20136. https:\/\/doi.org\/10.2967\/jnumed.121.262426.","journal-title":"Soc Nuclear Med"},{"issue":"4","key":"7201_CR27","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2967\/jnumed.123.266806","volume":"65","author":"C Li","year":"2024","unstructured":"Li C, Chen Q, Tian Y, Chen J, Xu K, Xiao Z, Zhong J, Wu J, Wen B, He Y. 68Ga-FAPI-04 PET\/CT in Non-Small cell lung cancer: accurate evaluation of lymph node metastasis and correlation with fibroblast activation protein expression. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2024;65(4):527\u201332. https:\/\/doi.org\/10.2967\/jnumed.123.266806.","journal-title":"Soc Nuclear Med"},{"issue":"2","key":"7201_CR28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1158\/1078-0432.CCR-21-3693","volume":"28","author":"Y Masugi","year":"2022","unstructured":"Masugi Y, Abe T, Yamazaki K, Ueno A, Sakamoto M. Three distinct stroma types in human pancreatic cancer identified by image analysis of fibroblast subpopulations and Collagen-Response. Clin cancer Research: Official J Am Association Cancer Res. 2022;28(2):427. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3693.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"50","key":"7201_CR29","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA. 2013;110(50):20212\u20137. https:\/\/doi.org\/10.1073\/pnas.1320318110.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"7201_CR30","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1158\/2326-6066.CIR-18-0098","volume":"6","author":"V Cremasco","year":"2018","unstructured":"Cremasco V, Astarita JL, Grauel AL, Keerthivasan S, MacIsaac K, Woodruff MC, Wu M, Spel L, Santoro S, Amoozgar Z, Laszewski T, Migoni SC, Knoblich K, Fletcher AL, LaFleur M, Wucherpfennig KW, Pure E, Dranoff G, Carroll MC, Turley SJ. FAP delineates heterogeneous and functionally divergent stromal cells in Immune-Excluded breast tumors. Cancer Immunol Res. 2018;6(12):1472\u201385. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0098.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"7201_CR31","doi-asserted-by":"publisher","first-page":"e170490","DOI":"10.1172\/JCI170490","volume":"134","author":"K Li","year":"2024","unstructured":"Li K, Liu W, Yu H, Chen J, Tang W, Wang J, Qi M, Sun Y, Xu X, Zhang J, Li X, Guo W, Li X, Song S, Tang S. 68Ga-FAPI PET imaging monitors response to combined TGF-\u03b2R Inhibition and immunotherapy in metastatic colorectal cancer. J Clin Investig. 2024;134(4):e170490. https:\/\/doi.org\/10.1172\/JCI170490.","journal-title":"J Clin Investig"},{"issue":"10","key":"7201_CR32","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.2967\/jnumed.123.265712","volume":"64","author":"M Wu","year":"2023","unstructured":"Wu M, Wang Y, Yang Q, Wang X, Yang X, Xing H, Sang X, Li X, Zhao H, Huo L. Comparison of baseline 68Ga-FAPI and 18F-FDG PET\/CT for prediction of response and clinical outcome in patients with unresectable hepatocellular carcinoma treated with PD-1 inhibitor and lenvatinib. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2023;64(10):1532\u20139. https:\/\/doi.org\/10.2967\/jnumed.123.265712.","journal-title":"Soc Nuclear Med"},{"issue":"2","key":"7201_CR33","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2214\/AJR.16.16532","volume":"208","author":"S Sheikhbahaei","year":"2017","unstructured":"Sheikhbahaei S, Mena E, Yanamadala A, Reddy S, Solnes LB, Wachsmann J, Subramaniam RM. The value of FDG PET\/CT in treatment response assessment, Follow-Up, and surveillance of lung cancer. AJR Am J Roentgenol. 2017;208(2):420\u201333. https:\/\/doi.org\/10.2214\/AJR.16.16532.","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"7201_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13550-020-00639-9","volume":"10","author":"X Wu","year":"2020","unstructured":"Wu X, Huang Y, Zhao Q, Wang L, Song X, Li Y, Jiang L. PD-L1 expression correlation with metabolic parameters of FDG PET\/CT and clinicopathological characteristics in non-small cell lung cancer. EJNMMI Res. 2020;10(1):51. https:\/\/doi.org\/10.1186\/s13550-020-00639-9.","journal-title":"EJNMMI Res"},{"issue":"5","key":"7201_CR35","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s12149-020-01451-0","volume":"34","author":"B Hu","year":"2020","unstructured":"Hu B, Chen W, Zhang Y, Shi H, Cheng D, Xiu Y. 18F-FDG maximum standard uptake value predicts PD-L1 expression on tumor cells or tumor-infiltrating immune cells in non-small cell lung cancer. Ann Nucl Med. 2020;34(5):322\u20138. https:\/\/doi.org\/10.1007\/s12149-020-01451-0.","journal-title":"Ann Nucl Med"},{"issue":"9","key":"7201_CR36","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00259-019-04348-x","volume":"46","author":"M Jreige","year":"2019","unstructured":"Jreige M, Letovanec I, Chaba K, Renaud S, Rusakiewicz S, Cristina V, Peters S, Krueger T, de Leval L, Kandalaft LE, Nicod-Lalonde M, Romero P, Prior JO, Coukos G, Schaefer N. 18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 Blockade in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2019;46(9):1859\u201368. https:\/\/doi.org\/10.1007\/s00259-019-04348-x.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07201-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07201-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07201-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T05:52:20Z","timestamp":1751435540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07201-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7201"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07201-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"4 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Clinical Research Ethics Committee of our institution (institutional review board approval no. SDZLEC2021\u2013112\u201302).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consents were obtained from all enrolled patients of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the studied data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}